Mylan launched a $26B hostile tender offer for Perrigo (announced April 2015, tender period closed November 13, 2015). Only 40% of Perrigo shares tendered, below the 50% threshold required, causing the bid to fail. Counted as a publicly announced terminated mega-deal. Perrigo spent ~$100M on takeover defense.
Key facts
AnnouncedNov 13, 2015
Deal value$26.0B
Deal typeAcquisition/Merger
Therapeutic areaConsumer healthcare / OTC
IndicationsConsumer healthcare / OTC
Key assetsPerrigo OTC and store-brand pharmaceuticals portfolio
MechanismOTC and store-brand generic pharmaceuticals